Previous 10 | Next 10 |
Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated ...
Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated ...
Schmitt Industries (NASDAQ: SMIT ) +13% on $2M stock repurchase plan . More news on: Schmitt Industries, Inc., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Stocks on the move, Read more ...
Omeros (NASDAQ: OMER ) is up 4% premarket on light volume in response to positive data from a pivotal Phase 2 clinical trial evaluating narsoplimab (OMS721) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (blood clots in tiny...
– 56 Percent of All Narsoplimab-Treated Patients Were Complete Responders by Primary Endpoint, Achieving Full Set of Response Criteria Agreed by FDA; 68 Percent Primary-Endpoint Complete Response Rate for Those Who Received Protocol-Specified Treatment of At Least 4 Weeks of Dosing &...
Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The positively received and well-attended presentation about the company’s ce...
-- GPR174 Deficiency Improves Outcomes in Animal Tumor Models -- Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals. The studies were c...
Omeros ( OMER ) is one of my favorite speculative biotech picks. This article reviews my current thinking on its prospects coming out of its recent Q3 earnings CC. Omeros has been a challenging hold of late as its share price forms jagged peaks only to soon fall in exhaustion from the effort...
Image source: The Motley Fool. Omeros (NASDAQ: OMER) Q3 2019 Earnings Call Nov 12, 2019 , 4:30 p.m. ET Operator Continue reading
Omeros Corporation (OMER) Q3 2019 Earnings Conference Call November 12, 2019 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Conference Call Participants ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 09:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
$118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment Repurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 419.5% to $0.24 on volume of 2,920,436,648 shares Greenwave Technology Solutions Inc. (GWAV) rose 147.7% to $0.1481 on volume of 1,864,631,229 shares Faraday Future Intelligent Electric Inc. (FF...